^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer

Published date:
11/01/2023
Excerpt:
An 81-year-old male diagnosed with unresectable epithelioid malignant mesothelioma...NGS demonstrated homozygous MTAP deletion and a PIK3CA mutation….MRTX1719 was resumed at 100 mg q.d. p.o. without recurrence of diarrhea. The first on-study disease assessment at cycle 2 day 20 demonstrated stable disease with a 13% reduction of target lesions. The subsequent disease assessment at cycle 4 day 20 achieved RECIST-defined partial response with a 30.7% reduction of target lesions, and despite dose interruption, disease assessment on cycle 6 day 9 showed ongoing confirmed partial response...
DOI:
https://doi.org/10.1158/2159-8290.CD-23-0669